Inactive Instrument

News XBiotech Inc Nasdaq

Equities

End-of-day quote Nasdaq Other stock markets
-	-

15/03	XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04/01	XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

XBiotech: Q1 Earnings Snapshot	10/05	AQ
XBiotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/03	CI
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	04/01	GL
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	04/01	GL
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	04/01	AQ
XBiotech Inc. to Begin Constructing New R&D Facility on Its 48-Acre Campus	04/01	CI
XBiotech Inc. announced that it expects to receive $10 million in funding	03/01	CI
Dr. Alan Kivitz to Chair XBiotech s Natrunix Program in Rheumatoid Arthritis	15/11	AQ
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis	14/11	GL
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis	14/11	AQ
Xbiotech Appoints Alan Kivitz M.D. Lead Investigator & Study Chairman for Its Clinical Research Program for Natrunix in Rheumatoid Arthritis	14/11	CI
XBiotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke	26/23/26	GL
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke	26/23/26	AQ
Xbiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, A Novel Candidate Therapy for Stroke	26/23/26	CI
XBiotech Inc.(NasdaqGS:XBIT) dropped from S&P Global BMI Index	18/23/18	CI
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	30/23/30	GL
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	30/23/30	AQ
Xbiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	30/23/30	CI
XBiotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+201.5% on SUPER MICRO COMPUTER since our purchase on February 17, 2023

Replicate our performance

fermer